Actively Recruiting
Phase 1 Trial of Personalized Neoantigen-Primed Dendritic Cell Vaccine After Surgery for Advanced Gastric, Liver, Lung, and Colorectal Cancers
Led by Sichuan University · Updated on 2025-02-28
80
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a personalized neoantigen-primed dendritic cell DC vaccine therapy for patients who have undergone surgery for locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, or colorectal cancer. This is a Phase 1, prospective exploratory trial aiming to explore biomarkers related to treatment response and side effects. The study enrolls patients who have received standard adjuvant treatment after surgery, with tumors analyzed by whole exome sequencing to identify possible neoantigens. The investigational treatment involves subcutaneous administration of DC vaccines primed with synthesized peptides based on each patients tumor neoantigens. These vaccines are given every 2 to 3 weeks for a total of 3 to 5 doses. The trial is open-label and single-arm, focusing on this personalized cell therapy approach as an adjuvant treatment for postoperative cancer. Participants will be monitored for adverse events and treatment responses throughout the study. Key assessments include disease-free survival up to 5 years and overall survival up to 10 years. Safety and tolerability will be evaluated by recording treatment-related adverse events for 3 months after the last vaccine dose. The total study duration allows long-term follow-up to understand the vaccines impact and related biomarkers.
CONDITIONS
Brief Title
Personalized DC Vaccine for Postoperative Cancer
Research Team
Q
Qiu Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here